Edwards Lifesciences (EW) PT Raised to $123 at Piper Jaffray
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Edwards Lifesciences Reports First Quarter Results
April 26, 2016 4:15 PM EDTIRVINE, Calif., April 26, 2016 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today reported financial results for the quarter ended March 31, 2016.
First Quarter Highlights:
Sales grew 18.1% to $697.3 million, and underlying1 sales were up 19.7% THVT sales grew 37.0%, and underlying sales were up 38.3% GAAP EPS was $0.66, an increase of 17.9%, and adjusted2 EPS grew 24.6% to $0.71 2016 sales guidance raised to $2.7 - $3.0 billion from $2.6 - $2.85... More